MarginsXMarginsX
Home › Markets › Health Care › CLYM

Climb Bio Inc. (CLYM)

CLYM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.94
-4.05% on the day
Market cap
$583.9M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCLYM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001768446
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
9.1 months
$39.7M cash at September 30, 2026
Share count, 1 year
-13.9%
2025-10-31 to 2026-10-30 · +113.0% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$39.7M cash; operating cash flow -$13.1M a quarter.Report 2026-09-30
Shares outstanding58,738,178 (2026-10-30); 68,184,435 a year earlier; 27,572,664 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $780K, sold $2.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$14.6M-$12.0M$39.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$13.5M-$10.5M$44.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$13.7M-$14.4M$8.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$17.5M-$15.6M$35.7MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$12.9M-$12.1M$25.8MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$8.7M-$11.1M$22.7MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$20.8M-$15.4M$29.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$8.4M-$5.5M$87.2MNo debt tagsNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-05
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 326 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.7%
1 month+0.5%
3 months-29.7%
Year to date+159.0%
1 year+454.0%
From 52-week high-41.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
GERNGeron Corporation$0.9419-2.60%$606.8M
HELPHelus Pharma Inc.$7.67-13.53%$560.4M
EVOEvotec SE$1.56-1.27%$555.0M
ABUSArbutus Biopharma Corporation$4.04-1.22%$619.3M
ZVRAZevra Therapeutics Inc.$9.25+1.87%$550.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier